Filing Flows

Filing Flows › Companies › Vir Biotechnology › Cash flow

Vir Biotechnology cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$106M in Q3 2026 · −$142M over twelve months

Operating cash flow−$106M
Capital spending−$34K
Free cash flow−$106M

Analysis

In Q3 2026, Vir Biotechnology generated −$106M of operating cash flow and spent $34K on capital projects, leaving free cash flow of −$106M. That is $61.8M more than in Q3 2025 (−$168M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$141M; the largest uses were operating cash flow ($141M), other investing ($53.3M), capital spending ($804K); besides operations, cash came from other financing ($240M), shares issued ($3.2M); the cash balance rose by $48.5M.

Operating cash flow was −$106M against net income of −$96.3M. The largest differences: stock-based pay +$10.5M, prepaid and other assets −$8.9M, payables −$6.4M.

Free cash flow

Vir Biotechnology: free cash flow by quarterVir Biotechnology: free cash flow by quarter−$89.6MQ4 2024−$79.7MQ1 2025−$123MQ2 2025−$168MQ3 2025−$26.2MQ4 2025−$133MQ1 2026$123MQ2 2026−$106MQ3 2026
Operating cash flow less capital spending.
Vir Biotechnology: operating cash flow against capital spendingVir Biotechnology: operating cash flow against capital spendingOperating cash flowCapital spending−$87.6M$2.0MQ4 2024−$78.1M$1.6MQ1 2025−$120M$2.5MQ2 2025−$168M$317KQ3 2025−$25.9M$348KQ4 2025−$132M$390KQ1 2026$123M$32KQ2 2026−$106M$34KQ3 2026
Latest (Q3 2026): Operating cash flow −$106M, Capital spending $34K.

Capital allocation, year by year

Vir Biotechnology: where the cash came from (up) and went (down), by fiscal yearVir Biotechnology: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$47.6MFY2021: Net borrowing −$259KFY2021: Shares issued $13.1MFY2021: Capital spending −$21.8M$13.1MFY2021FY2022: Operating cash flow $1.7BFY2022: Net borrowing −$260KFY2022: Shares issued $4.5MFY2022: Capital spending −$68.0M$1.7BFY2022FY2023: Operating cash flow −$779MFY2023: Net borrowing −$287KFY2023: Shares issued $3.5MFY2023: Capital spending −$21.6M$3.5MFY2023FY2024: Operating cash flow −$446MFY2024: Shares issued $790KFY2024: Asset sales $3.4MFY2024: Capital spending −$7.3M$4.2MFY2024FY2025: Operating cash flow −$392MFY2025: Shares issued $1.3MFY2025: Capital spending −$4.8M$1.3MFY2025
Over these 5 years operating cash flow totalled −$1.3M; the largest uses were operating cash flow ($1.7B) and capital spending ($124M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$455M
Debtnone
Net cash$455M
Cash runway3.2 years

Vir Biotechnology is burning cash: its operations consume cash, a free cash flow of −$142M a year at the current rate against $455M of cash and investments: a runway of about 3.2 years before any new financing.

Where the cash came from and went

Vir Biotechnology: sources (+) and uses (−) of cash, Q3 2026Vir Biotechnology: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$106MCash drawn (+) / kept (−)$59.9MOther investing$44.6MShares issued$1.6MCapital spending−$34K
Vir Biotechnology: sources (+) and uses (−) of cash, TTM to Q3 2026Vir Biotechnology: sources (+) and uses (−) of cash, TTM to Q3 2026Other financing$240MOperating cash flow−$141MOther investing−$53.3MCash drawn (+) / kept (−)−$48.5MShares issued$3.2MCapital spending−$804K

From profit to cash

Vir Biotechnology: net income to operating cash flow, Q3 2026Vir Biotechnology: net income to operating cash flow, Q3 2026Net income−$96.3MDepreciation & amortization$2.8MStock-based pay$10.5MPayables−$6.4MAccrued liabilities−$6.2MPrepaid and other assets−$8.9MOperating cash flow−$106M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$106M−$34K$1.6M$59.9M−$106M
Q2 2026$123M−$32K$1.4M−$4.6M$123M
Q1 2026−$132M−$390K$163M−$42.0M−$133M
Q4 2025−$25.9M−$348K$1K−$61.8M−$26.2M
Q3 2025−$168M−$317K$101K$127M−$168M
Q2 2025−$120M−$2.5M$649K$61.7M−$123M
Q1 2025−$78.1M−$1.6M$598K−$49.3M−$79.7M
Q4 2024−$87.6M−$2.0M$89K−$54.4M−$89.6M

Vir Biotechnology: income statement and cash flow

Vir Biotechnology, Q2 2026: revenue $239M (197× year over year), operating margin 30.7%. The chart follows the revenue to costs, profit and cash.

Vir Biotechnology: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.